PRTC vs. GNS, ERGO, SLN, OXB, HZD, VRP, FARN, AVCT, ARIX, and BVXP
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Arix Bioscience (ARIX), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.
PureTech Health vs.
PureTech Health (LON:PRTC) and Genus (LON:GNS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, community ranking, valuation, earnings and risk.
Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
PureTech Health has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.
79.9% of PureTech Health shares are owned by institutional investors. Comparatively, 77.8% of Genus shares are owned by institutional investors. 15.9% of PureTech Health shares are owned by insiders. Comparatively, 0.8% of Genus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Genus has a net margin of 1.18% compared to PureTech Health's net margin of 0.00%. Genus' return on equity of 0.43% beat PureTech Health's return on equity.
PureTech Health presently has a consensus price target of GBX 455, indicating a potential upside of 228.76%. Genus has a consensus price target of GBX 2,150, indicating a potential upside of 20.65%. Given PureTech Health's higher probable upside, research analysts plainly believe PureTech Health is more favorable than Genus.
In the previous week, Genus had 2 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Genus and 0 mentions for PureTech Health. Genus' average media sentiment score of 0.11 beat PureTech Health's score of 0.00 indicating that Genus is being referred to more favorably in the news media.
PureTech Health received 178 more outperform votes than Genus when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 70.54% of users gave Genus an outperform vote.
Summary
Genus beats PureTech Health on 10 of the 17 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PRTC Stock Alerts